NG

NICE NG131

Prostate Cancer Guide

Metastatic Prostate Cancer

Treatment recommendations for newly diagnosed and hormone-relapsed metastatic disease.

Newly Diagnosed Metastatic Cancer (1.5.1-1.5.5)

First-Line Treatment (1.5.1)

Offer people with newly diagnosed metastatic prostate cancer:

  • Hormone therapy AND
  • Docetaxel chemotherapy

Additional Options (1.5.4)

Consider offering:

  • Abiraterone with prednisolone OR
  • Enzalutamide

Important: Discuss risks and benefits of docetaxel chemotherapy with patients. Prescribing should follow NICE's guidance on prescribing medicines.

Hormone-Relapsed Metastatic Cancer (1.5.6-1.5.11)

Treatment Options (1.5.6)

Offer people with hormone-relapsed metastatic prostate cancer:

  • Abiraterone with prednisolone OR
  • Enzalutamide OR
  • Docetaxel chemotherapy

Further Options (1.5.9)

Consider offering:

  • Cabazitaxel with prednisolone OR
  • Radium-223 dichloride

Clinical Note: Treatment selection for hormone-relapsed disease should be individualized based on patient factors, prior treatments, and disease characteristics. Always discuss risks and benefits with the patient.

Treatment Summary

Disease StatusRecommended Treatment
Newly Diagnosed MetastaticHormone therapy + Docetaxel
Newly Diagnosed (Alternative)Consider: Abiraterone or Enzalutamide
Hormone-RelapsedAbiraterone OR Enzalutamide OR Docetaxel
Hormone-Relapsed (Further)Consider: Cabazitaxel or Radium-223

GP Role in Metastatic Disease

As a GP, your role includes:

  • Monitoring: Regular assessment of treatment tolerance and side effects
  • Support: Provide counseling and psychosocial support
  • Liaison: Maintain close communication with oncology services
  • Symptom Management: Address pain, fatigue, and other symptoms
  • Medication Management: Manage side effects of chemotherapy and hormone therapy
  • Palliative Care: Coordinate palliative and end-of-life care as appropriate
  • Family Support: Provide support to patients' families and carers